Advertisement
ACAD vs STOK
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ACAD is a Hold and STOK is a Buy.
ACAD in +4.88% Uptrend, growing for three consecutive days on November 04, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where ACAD advanced for three days, in 189 of 253 cases, the price rose further within the following month. The odds of a continued upward trend are 75%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where ACAD's RSI Oscillator exited the oversold zone, 15 of 23 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 65%.
ACAD may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 42 of 61 cases where ACAD's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 69%.
The Momentum Indicator moved below the 0 level on November 09, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ACAD as a result. In 61 of 96 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 64%.
The Moving Average Convergence Divergence Histogram (MACD) for ACAD turned negative on November 10, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In 35 of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at 76%.
The 50-day moving average for ACAD moved below the 200-day moving average on November 02, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ACAD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 70%.
The Aroon Indicator for ACAD entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 28 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 80 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.800) is normal, around the industry mean (3.498). P/E Ratio (9.394) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (4.168) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 80 (best 1 - 100 worst), indicating slightly worse than average price growth. ACAD’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 82 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 97 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ACAD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
STOK's RSI Oscillator recovers from oversold territory
The RSI Indicator for STOK moved out of oversold territory on October 14, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 27 similar instances when the indicator left oversold territory. In 24 of the 27 cases the stock moved higher. This puts the odds of a move higher at 89%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on STOK as a result. In 72 of 82 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 88%.
The Moving Average Convergence Divergence (MACD) for STOK just turned positive on October 15, 2026. Looking at past instances where STOK's MACD turned positive, the stock continued to rise in 39 of 47 cases over the following month. The odds of a continued upward trend are 83%.
STOK moved above its 50-day moving average on November 09, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for STOK crossed bullishly above the 50-day moving average on November 10, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 18 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 61%.
Following a +6.29% 3-day Advance, the price is estimated to grow further. Considering data from situations where STOK advanced for three days, in 269 of 304 cases, the price rose further within the following month. The odds of a continued upward trend are 88%.
STOK may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where STOK declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
The Aroon Indicator for STOK entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 29 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.956) is normal, around the industry mean (3.498). P/E Ratio (-7.829) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (63.291) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 51 (best 1 - 100 worst), indicating steady price growth. STOK’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 87 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. STOK’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock better than average.
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
ACAD | STOK | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 16 | 33 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 80 Overvalued | 29 Undervalued | |
PROFIT vs RISK RATING 1..100 | 97 | 87 | |
SMR RATING 1..100 | 28 | 98 | |
PRICE GROWTH RATING 1..100 | 80 | 51 | |
P/E GROWTH RATING 1..100 | 82 | 98 | |
SEASONALITY SCORE 1..100 | 75 | 23 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
STOK's Valuation (29) in the null industry is somewhat better than the same rating for ACAD (80) in the Biotechnology industry. This means that STOK’s stock grew somewhat faster than ACAD’s over the last 12 months.
STOK's Profit vs Risk Rating (87) in the null industry is in the same range as ACAD (97) in the Biotechnology industry. This means that STOK’s stock grew similarly to ACAD’s over the last 12 months.
ACAD's SMR Rating (28) in the Biotechnology industry is significantly better than the same rating for STOK (98) in the null industry. This means that ACAD’s stock grew significantly faster than STOK’s over the last 12 months.
STOK's Price Growth Rating (51) in the null industry is in the same range as ACAD (80) in the Biotechnology industry. This means that STOK’s stock grew similarly to ACAD’s over the last 12 months.
ACAD's P/E Growth Rating (82) in the Biotechnology industry is in the same range as STOK (98) in the null industry. This means that ACAD’s stock grew similarly to STOK’s over the last 12 months.
| ACAD | STOK | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 65% | 2 days ago 89% |
| Stochastic ODDS (%) | 2 days ago 69% | 2 days ago 84% |
| Momentum ODDS (%) | 2 days ago 64% | 2 days ago 88% |
| MACD ODDS (%) | 2 days ago 76% | 2 days ago 83% |
| TrendWeek ODDS (%) | 2 days ago 68% | 2 days ago 85% |
| TrendMonth ODDS (%) | 2 days ago 71% | 2 days ago 82% |
| Advances ODDS (%) | 8 days ago 75% | 3 days ago 88% |
| Declines ODDS (%) | 3 days ago 70% | 13 days ago 85% |
| BollingerBands ODDS (%) | 2 days ago 67% | 2 days ago 85% |
| Aroon ODDS (%) | 2 days ago 68% | 2 days ago 84% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ACAD’s FA Score shows that 1 FA rating(s) are green while STOK’s FA Score has 1 green FA rating(s).
- ACAD’s FA Score: 1 green, 4 red.
- STOK’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ACAD’s TA Score shows that 3 TA indicator(s) are bullish while STOK’s TA Score has 7 bullish TA indicator(s).
- ACAD’s TA Score: 3 bullish, 6 bearish.
- STOK’s TA Score: 7 bullish, 3 bearish.
Price Growth
ACAD (@Biotechnology) experienced а -11.13% price change this week, while STOK (@Biotechnology) price change was +0.82% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +4.90%. For the same industry, the average monthly price growth was -2.72%, and the average quarterly price growth was -13.41%.
Reported Earning Dates
ACAD is expected to report earnings on Mar 01, 2027.
STOK is expected to report earnings on Mar 16, 2027.
Industries' Descriptions
@Biotechnology (+4.90% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
ACAD and
Correlation & Price change
A.I.dvisor indicates that over the last year, ACAD has been loosely correlated with ZURA. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if ACAD jumps, then ZURA could also see price increases.
| Ticker / NAME | Correlation To ACAD | 1D Price Change % | ||
|---|---|---|---|---|
| ACAD | 100% | +10.79% | ||
| ZURA - ACAD | 58% Loosely correlated | +13.31% | ||
| DNLI - ACAD | 45% Loosely correlated | -2.36% | ||
| CLDX - ACAD | 45% Loosely correlated | -1.89% | ||
| MGTX - ACAD | 45% Loosely correlated | +1.37% | ||
| STOK - ACAD | 44% Loosely correlated | -1.80% | ||
More | ||||
STOK and
Correlation & Price change
A.I.dvisor indicates that over the last year, STOK has been loosely correlated with RCKT. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if STOK jumps, then RCKT could also see price increases.
| Ticker / NAME | Correlation To STOK | 1D Price Change % | ||
|---|---|---|---|---|
| STOK | 100% | -1.80% | ||
| RCKT - STOK | 53% Loosely correlated | -3.16% | ||
| DYN - STOK | 53% Loosely correlated | -3.76% | ||
| TSHA - STOK | 52% Loosely correlated | -2.17% | ||
| SLDB - STOK | 50% Loosely correlated | +2.14% | ||
| QTTB - STOK | 49% Loosely correlated | -0.11% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| BFEW | 21.91 | N/A | N/A |
| FT Vest Laddered U.S. Equity Equal Weight Buffer ETF (BFEW) | |||
| ORBX | 38.23 | -0.02 | -0.04% |
| Global X Space Tech ETF (ORBX) | |||
| USPX | 65.51 | -0.28 | -0.43% |
| Franklin U.S. Equity Index ETF (USPX) | |||
| AGOX | 33.83 | -0.23 | -0.69% |
| Adaptive Alpha Opportunities ETF (AGOX) | |||
| BABX | 14.43 | -0.79 | -5.19% |
| GraniteShares 2x Long BABA Daily ETF (BABX) | |||